The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay
Open accessAbstract
The main reason why tumours are not controlled by the immune system is that, unlike pathogens, they do not express potent tumour rejection antigens (TRAs). Tumour vaccination aims at stimulating a systemic immune response targeted to, mostly weak, antigens expressed in the disseminated tumour lesions. Main challenges in developing effective vaccination protocols are the identification of potent and broadly expressed TRAs and effective adjuvants to stimulate a robust and durable immune response. Here we describe an alternative approach in which the expression of new, and thereby potent, antigens are induced in tumour cells by inhibiting nonsense-mediated messenger RNA decay (NMD). Small interfering RNA (siRNA)-mediated inhibition of NMD in tumour cells led to the expression of new antigenic determinants and their immune-mediated rejection. In subcutaneous and metastatic tumour models, tumour-targeted delivery of NMD factor-specific siRNAs conjugated to oligonucleotide aptamer ligands led to significant inhibition of tumour growth that was superior to that of vaccination with granulocyte–macrophage colony-stimulating factor (GM-CSF)-expressing irradiated tumour cells, and could be further enhanced by co-stimulation. Tumour-targeted NMD inhibition forms the basis of a simple, broadly useful, and clinically feasible approach to enhance the antigenicity of disseminated tumours leading to their immune recognition and rejection. The cell-free chemically synthesized oligonucleotide backbone of aptamer–siRNAs reduces the risk of immunogenicity and enhances the feasibility of generating reagents suitable for clinical use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Pathogen Recognition and Innate Immunity
Akira, S., Uematsu, S., & Takeuchi, O. (2006) · Cell · doi:10.1016/j.cell.2006.02.015 · Cited by 11,952
Tuerk, C., & Gold, L. (1990) · Science · doi:10.1126/science.2200121 · Cited by 10,405
In vitro selection of RNA molecules that bind specific ligands
Ellington, A. D., & Szostak, J. W. (1990) · Nature · doi:10.1038/346818a0 · Cited by 9,812
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
T cell receptor antagonist peptides induce positive selection
Hogquist, K. A., Jameson, S. C., Heath, W. R., Howard, J. L., Bevan, M. J., & Carbone, F. R. (1994) · Cell · doi:10.1016/0092-8674(94)90169-4 · Cited by 2,858
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Keefe, A. D., Pai, S., & Ellington, A. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3141 · Cited by 2,289
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
Ng, E. W. M., Shima, D. T., Calias, P., Cunningham, E. T., Guyer, D. R., & Adamis, A. P. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1955 · Cited by 1,588
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA
Judge, A. D., Sood, V., Shaw, J. R., Fang, D., McClintock, K., & MacLachlan, I. (2005) · Nature Biotechnology · doi:10.1038/nbt1081 · Cited by 1,250
Nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics
Maquat, L. E. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1310 · Cited by 1,214
van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020
Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras
McNamara, J. O., Andrechek, E. R., Wang, Y., Viles, K. D., Rempel, R. E., Gilboa, E., Sullenger, B. A., & Giangrande, P. H. (2006) · Nature Biotechnology · doi:10.1038/nbt1223 · Cited by 1,002
Self-citationNonsense-mediated mRNA decayin health and disease
Frischmeyer, P. A. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.10.1893 · Cited by 992
Aptamers: An Emerging Class of Therapeutics
Nimjee, S. M., Rusconi, C. P., & Sullenger, B. A. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.062904.144915 · Cited by 937
Overwijk, W. W., Theoret, M. R., Finkelstein, S. E., Surman, D. R., de Jong, L. A., Vyth-Dreese, F. A., Dellemijn, T. A., Antony, P. A., Spiess, P. J., Palmer, D. C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030590 · Cited by 925
Mendell, J. T., Sharifi, N. A., Meyers, J. L., Martinez-Murillo, F., & Dietz, H. C. (2004) · Nature Genetics · doi:10.1038/ng1429 · Cited by 876
Quezada, S. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27745 · Cited by 700
A listing of human tumor antigens recognized by T cells
Renkvist, N., Castelli, C., Robbins, P. F., & Parmiani, G. (2001) · Cancer Immunology, Immunotherapy · doi:10.1007/s002620000169 · Cited by 694
Nonsense-mediated decay approaches the clinic
Holbrook, J. A., Neu-Yilik, G., Hentze, M. W., & Kulozik, A. E. (2004) · Nature Genetics · doi:10.1038/ng1403 · Cited by 596
Dassie, J. P., Liu, X.-Y., Thomas, G. S., Whitaker, R. M., Thiel, K. W., Stockdale, K. R., Meyerholz, D. K., McCaffrey, A. P., McNamara, J. O., & Giangrande, P. H. (2009) · Nature Biotechnology · doi:10.1038/nbt.1560 · Cited by 589
Self-citationLupold, S. E., Hicke, B. J., Lin, Y. H., & Coffey, D. S. (2002) · PubMed · Cited by 566
Cancer Immunotherapy by Dendritic Cells
Melief, C. J. M. (2008) · Immunity · doi:10.1016/j.immuni.2008.08.004 · Cited by 508
A listing of human tumor antigens recognized by T cells: March 2004 update
Novellino, L., Castelli, C., & Parmiani, G. (2005) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-004-0560-6 · Cited by 466
Duval, A., & Hamelin, R. (2002) · PubMed · Cited by 404
The Makings of a Tumor Rejection Antigen
Gilboa, E. (1999) · Immunity · doi:10.1016/s1074-7613(00)80101-6 · Cited by 381
Self-citationSpinning molecular immunology into successful immunotherapy
Pardoll, D. M. (2002) · Nature Reviews Immunology · doi:10.1038/nri774 · Cited by 360
Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice
McNamara, J. O., Kolonias, D., Pastor, F., Mittler, R. S., Chen, L., Giangrande, P. H., Sullenger, B., & Gilboa, E. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33365 · Cited by 310
Self-citationImmunogenic cancer cell death: a key-lock paradigm
Tesniere, A., Apetoh, L., Ghiringhelli, F., Joza, N., Panaretakis, T., Kepp, O., Schlemmer, F., Zitvogel, L., & Kroemer, G. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.05.007 · Cited by 307
The multiple lives of NMD factors: balancing roles in gene and genome regulation
Isken, O., & Maquat, L. E. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2402 · Cited by 305
Sæterdal, I., Bjørheim, J., Lislerud, K., Gjertsen, M. K., Bukholm, I. K., Olsen, O. C., Nesland, J. M., Eriksen, J. A., Møller, M., Lindblom, A., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.231326898 · Cited by 273
The promise of cancer vaccines
Gilboa, E. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1359 · Cited by 267
Self-citationOligonucleotides as Research, Diagnostic, and Therapeutic Agents
Gold, L. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.23.13581 · Cited by 266
Separable Roles for rent1/hUpf1 in Altered Splicing and Decay of Nonsense Transcripts
Mendell, J. T., ap Rhys, C. M. J., & Dietz, H. C. (2002) · Science · doi:10.1126/science.1074428 · Cited by 260
Neff, C. P., Zhou, J., Remling, L., Kuruvilla, J., Zhang, J., Li, H., Smith, D. D., Swiderski, P., Rossi, J. J., & Akkina, R. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001581 · Cited by 259
hUPF2 Silencing Identifies Physiologic Substrates of Mammalian Nonsense-Mediated mRNA Decay
Wittmann, J., Hol, E. M., & Jäck, H.-M. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.4.1272-1287.2006 · Cited by 240
Wheeler, L. A., Trifonova, R., Vrbanac, V., Basar, E., McKernan, S., Xu, Z., Seung, E., Deruaz, M., Dudek, T., Einarsson, J. I., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45876 · Cited by 227
mRNA quality control: An ancient machinery recognizes and degrades mRNAs with nonsense codons
Behm-Ansmant, I., Kashima, I., Rehwinkel, J., Saulière, J., Wittkopp, N., & Izaurralde, E. (2007) · FEBS Letters · doi:10.1016/j.febslet.2007.05.027 · Cited by 212
Chemotherapy and radiotherapy: Cryptic anticancer vaccines
Ma, Y., Kepp, O., Ghiringhelli, F., Apetoh, L., Aymeric, L., Locher, C., Tesniere, A., Martins, I., Ly, A., Haynes, N. M., et al. (2010) · Seminars in Immunology · doi:10.1016/j.smim.2010.03.001 · Cited by 193
Natural immunity to cancer in humans
Bindea, G., Mlecnik, B., Fridman, W.-H., Pagès, F., & Galon, J. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.02.006 · Cited by 192
Assembling OX40 Aptamers on a Molecular Scaffold to Create a Receptor-Activating Aptamer
Dollins, C. M., Nair, S., Boczkowski, D., Lee, J., Layzer, J. M., Gilboa, E., & Sullenger, B. A. (2008) · Chemistry & Biology · doi:10.1016/j.chembiol.2008.05.016 · Cited by 183
Self-citationProstate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts
Ni, X., Zhang, Y., Ribas, J., Chowdhury, W. H., Castanares, M. A., Zhang, Z., Laiho, M., DeWeese, T. L., & Lupold, S. E. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45109 · Cited by 143
Recognition and elimination of nonsense mRNA
Mühlemann, O., EBERLE, A., Stalder, L., & Orozco, R. Z. (2008) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2008.06.012 · Cited by 141
Pastor, F., Kolonias, D. S., McNamara, J. O., & Gilboa, E. (2011) · Molecular Therapy · doi:10.1038/mt.2011.145 · Cited by 139
Self-citationCancer immunotherapy: breaking the barriers to harvest the crop
Pardoll, D. M., & Allison, J. P. (2004) · Nature Medicine · doi:10.1038/nm0904-887 · Cited by 135
Specificity in cancer immunotherapy
Schietinger, A., Philip, M., & Schreiber, H. W. (2008) · Seminars in Immunology · doi:10.1016/j.smim.2008.07.001 · Cited by 126
Usuki, F., Yamashita, A., Kashima, I., Higuchi, I., Osame, M., & Ohno, S. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.04.011 · Cited by 108
Jinushi, M., Hodi, F. S., & Dranoff, G. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00618.x · Cited by 91
Blocking the Initiation of Coagulation by RNA Aptamers to Factor VIIa
Lyerly, H. K., Lawson, J., Rusconi, C., Yeh, A., & Sullenger, B. A. (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614126 · Cited by 90
Aagaard, L., Amarzguioui, M., Sun, G., SANTOS, L. V. D. S., Ehsani, A., Prydz, H., & Rossi, J. J. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300118 · Cited by 60
Can genes for mammographic density inform cancer aetiology?
Kelemen, L. E., Sellers, T. A., & Vachon, C. M. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2466 · Cited by 41
Cited by
Aptamers as targeted therapeutics: current potential and challenges
Zhou, J., & Rossi, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.199 · Cited by 2,221
Analysis of aptamer discovery and technology
Dunn, M. R., Jimenez, R. M., & Chaput, J. C. (2017) · Nature Reviews Chemistry · doi:10.1038/s41570-017-0076 · Cited by 938
The delivery of therapeutic oligonucleotides
Juliano, R. L. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw236 · Cited by 854
Quality and quantity control of gene expression by nonsense-mediated mRNA decay
Kurosaki, T., Popp, M. W., & Maquat, L. E. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0126-2 · Cited by 826
RNA-Based Therapeutics: Current Progress and Future Prospects
Burnett, J. C., & Rossi, J. J. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.008 · Cited by 819
Metadata
- Authors
- Pastor, F., Kolonias, D., Giangrande, P. H., & Gilboa, E.
- Venue
- Nature
- Published
- 2010-05
- Volume
- 465
- Issue
- 7295
- Pages
- 227-230
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2033013069
- Cited by
- 294
- References
- 51
- FWCI
- 7.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.